U.S. Capital Markets Stock News

NasdaqGM:NPCE
NasdaqGM:NPCEMedical Equipment

NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative

NeuroPace (NPCE) has just closed out FY 2025 with Q4 revenue of US$26.6 million and a basic EPS loss of US$0.08, while trailing twelve month figures show revenue of US$100.0 million and a basic EPS loss of US$0.66 as the company continues to operate at a loss. Over the past several quarters, the business has seen revenue move from US$21.5 million in Q4 2024 to US$26.6 million in Q4 2025, with quarterly basic EPS losses ranging between US$0.18 and US$0.26 before the latest US$0.08 print. This...
NasdaqCM:REAX
NasdaqCM:REAXReal Estate

Real Brokerage (REAX) Nears Breakeven In Q3 Which Tests Bears On Profitability Timeline

Real Brokerage (NasdaqCM:REAX) has just posted its FY 2025 third quarter scorecard, with revenue of US$568.5 million and a small net loss of US$0.4 million translating to basic EPS of US$0.00. Trailing 12 month revenue sits at about US$1.8 billion alongside a net loss of US$10.5 million and basic EPS of US$0.05. Those figures come at a time when investors are weighing ongoing losses against forecasts for faster growth and a path to profitability, putting the focus firmly on how margins evolve...
NasdaqGS:GOOGL
NasdaqGS:GOOGLInteractive Media and Services

Alphabet Faces AI Wrongful Death Case And Epic Android Settlement Impact

Google parent Alphabet (NasdaqGS:GOOGL) is facing a wrongful death lawsuit alleging its Gemini AI chatbot contributed to a user's suicide. The case is described as the first of its kind targeting Google's AI tools, putting a spotlight on mental health risks and AI safety standards. Separately, Google has settled a major antitrust dispute with Epic Games involving Play Store practices, agreeing to lower commissions and support alternative app stores on Android. These developments arrive...
NYSE:O
NYSE:ORetail REITs

Does Realty Income’s (O) Guidance Cut and Leadership Change Hint at a Shifting Income Strategy?

In late February 2026, Realty Income reported higher quarterly and full-year 2025 revenue and net income, issued 2026 earnings guidance of US$1.65–US$1.69 per share, and subsequently saw its stock rating cut to Hold from Buy by Freedom Capital Markets. Shortly after these updates, Realty Income also announced the planned departure of its Chief Legal Officer, underscoring both leadership transition and investor focus on how management will execute against modest 2026 guidance. We’ll now...
NYSE:TREX
NYSE:TREXBuilding

Assessing Trex Company (TREX) Valuation After Mixed Share Performance And Modest Undervaluation Estimate

What recent performance says about Trex Company (TREX) With no single headline event driving Trex Company (TREX) today, the stock’s recent performance is doing most of the talking for investors tracking entry or exit points. Over the past month the share price shows a return of about a 3% decline, while the past 3 months reflect a gain of roughly 17%. On a 1 year view, the stock is down around 31%, and longer 3 year and 5 year total returns are also negative. That mixed record contrasts with...
NYSE:EPRT
NYSE:EPRTREITs

Is Essential Properties Realty Trust (EPRT) Still Attractive After Recent Share Price Gains

If you are wondering whether Essential Properties Realty Trust is reasonably priced or starting to look expensive, you are not alone. The stock last closed at US$34.57, with returns of 3.4% over 7 days, 14.8% over 30 days, 15.0% year to date and 12.0% over the past year, which naturally raises questions about what is already reflected in the price. Recent attention on Essential Properties Realty Trust has largely focused on its role as a net lease REIT and how that business model fits into...
NYSE:WCC
NYSE:WCCTrade Distributors

Is It Too Late To Consider WESCO International (WCC) After Its 69% One Year Rally?

If you are wondering whether WESCO International's share price still reflects fair value after a strong run, this article walks through what the numbers are actually saying about the stock. The shares last closed at US$286.58, with returns of 13.7% year to date and 69.0% over the past year, although the stock has seen short term setbacks with 7 day and 30 day returns of 3.6% and 3.8% declines respectively. Recent market interest has been shaped by ongoing coverage of WESCO International as a...
NasdaqGS:FITB
NasdaqGS:FITBBanks

A Look At Fifth Third Bancorp (FITB) Valuation As Short Interest Falls And Growth Plans Gain Support

Fifth Third Bancorp (FITB) is back on investors’ radar after a sharp 31.3% drop in short interest, a wave of upbeat analyst commentary, and fresh branch expansion plans tied to its multi year growth strategy. See our latest analysis for Fifth Third Bancorp. At a share price of US$49.54, Fifth Third has given investors a 3.8% year to date share price return, while its 1 year total shareholder return of 26.9% points to momentum that has so far outweighed the recent 1 month pullback. This...
NasdaqGS:REAL
NasdaqGS:REALSpecialty Retail

A Look At The RealReal (REAL) Valuation After Strong Q4 Results And 2026 Growth Guidance

The RealReal (REAL) just paired a strong fourth quarter with fresh 2026 guidance, reporting higher year over year revenue, narrower net losses and its first full year of consistently positive adjusted EBITDA. See our latest analysis for RealReal. After this earnings and guidance update, RealReal’s latest share price of $12.13 comes after mixed short term moves, with a 4.30% 1 day share price return but a 17.54% 30 day share price decline, while the 1 year total shareholder return of 111.88%...
NasdaqGS:HUT
NasdaqGS:HUTSoftware

Is Hut 8’s AI Data Center Pivot Amid Heavy 2025 Losses Altering The Investment Case For Hut 8 (HUT)?

In February 2026, Hut 8 Corp. reported fourth-quarter 2025 revenue of US$88.49 million, full-year 2025 revenue of US$235.12 million, and a full-year net loss of US$226.15 million, while also announcing a partnership with Anthropic and Fluidstack to build AI data center infrastructure in the United States. The combination of deep losses alongside a push into AI-focused data centers highlights Hut 8’s effort to lessen its dependence on Bitcoin-linked income and broaden its infrastructure...
NYSE:TDY
NYSE:TDYElectronic

Assessing Teledyne Technologies (TDY) Valuation After New Defense Electronics And Unmanned Drone Initiatives

Teledyne Technologies (TDY) has drawn fresh attention after unveiling a Wideband Limiter aimed at protecting radar and electronic warfare systems from high power RF and directed energy threats, alongside a new unmanned drone collaboration. See our latest analysis for Teledyne Technologies. The recent run of product launches in electronic warfare, RF components and thermal imaging, together with a credit agreement tweak, comes against a strong 30 day share price return of 11.34% and a 1 year...
NYSE:UHS
NYSE:UHSHealthcare

Assessing Universal Health Services (UHS) Valuation After Recent Share Price Weakness

Recent performance snapshot Universal Health Services (UHS) has attracted investor attention after recent share price moves, with the stock showing mixed returns over the past week, month and past 3 months. Over the past day, the share price return was about 1.2% lower, while the past week shows a decline of roughly 12%. In contrast, returns for the month were close to flat, and the past 3 months reflect a decline of about 12%. See our latest analysis for Universal Health Services. Universal...
NasdaqGS:MNDY
NasdaqGS:MNDYSoftware

How Investors May Respond To monday.com (MNDY) Rapid ARR Gains And Efficient Customer Payback Period

In the past quarter, monday.com reported annual recurring revenue of US$1.34 billion alongside gross margins near 89%, underscoring robust demand for its cloud-based work management platform. An interesting angle is the company’s roughly 30-month payback period on customer acquisition costs, which highlights how efficiently it converts marketing spend into durable subscription revenue. Next, we’ll examine how this rapid ARR expansion and efficient customer acquisition influence monday.com’s...
NYSE:BIP
NYSE:BIPIntegrated Utilities

Is It Too Late To Consider Brookfield Infrastructure Partners (NYSE:BIP) After 35% One Year Rally?

If you are wondering whether Brookfield Infrastructure Partners is still good value at around US$38.94, the key question is how its current price lines up with what the underlying business might be worth. The unit price has been relatively firm recently, with a 6.3% move over the last 30 days and a 13.5% return year to date, while the 1 year return sits at 35.5% and the 5 year return at 39.8%. These moves sit against an ongoing stream of news about global infrastructure demand, financing...
NasdaqCM:CYRX
NasdaqCM:CYRXLife Sciences

Cryoport (CYRX) Q4 Loss Of US$0.21 Per Share Tests Bullish Margin Narratives

Cryoport FY 2025 earnings snapshot Cryoport (CYRX) has reported its FY 2025 fourth quarter with revenue of US$45.5 million and a basic EPS loss of US$0.21, alongside net income from continuing operations showing a loss of US$10.5 million. The company has seen quarterly revenue track between US$41.0 million and US$45.5 million across FY 2025, while basic EPS losses ranged from US$0.17 to US$0.23 per share, providing a clear picture of consistent top line scale but ongoing bottom line pressure...
NYSE:STVN
NYSE:STVNLife Sciences

Stevanato Group (NYSE:STVN) Margin Improvement To 12% Tests Bullish Earnings Narratives

Stevanato Group FY 2025 Earnings Snapshot Stevanato Group (NYSE:STVN) has put another solid quarter on the board for FY 2025, with Q3 revenue of €303.2 million and basic EPS of €0.13, alongside trailing twelve month EPS of €0.52 on €1.17 billion of revenue, capped by 22.6% earnings growth over the past year. The company has seen revenue move from €259.6 million in Q2 2024 to €303.2 million in Q3 2025, while quarterly EPS has ranged between €0.08 and €0.18 over that period, setting up a...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

STAAR Surgical (STAA) Posts US$80.4 Million Annual Loss Testing Turnaround Narratives

STAAR Surgical FY 2025 earnings snapshot STAAR Surgical (STAA) has wrapped up FY 2025 with Q4 revenue of US$57.8 million and a basic EPS loss of US$0.37, keeping the focus firmly on the path back to profitability. The company has seen quarterly revenue range from US$42.6 million to US$94.7 million since the start of 2024, while basic EPS has swung between a loss of US$1.10 and a profit of US$0.20. This sets up a mixed picture on margins that investors may view as an ongoing turnaround story...
NYSE:XPEV
NYSE:XPEVAuto

XPeng (XPEV) Valuation Check As Delivery Headwinds Meet New Models And Volkswagen AD Partnership

XPeng (XPEV) just reported February 2026 deliveries of 15,256 vehicles, alongside plans to roll out new models and supply its second generation assisted driving solution to Volkswagen, giving investors fresh data points to reassess the stock. See our latest analysis for XPeng. At a share price of US$16.17, XPeng has seen a 1 day share price return of 1.89%. However, the 7 day and year to date share price returns of 11.06% and 20.85% declines suggest momentum has cooled. This comes even as the...
NasdaqGS:CRCT
NasdaqGS:CRCTConsumer Durables

Cricut (CRCT) Margin Improvement Challenges Bearish Earnings Narratives After FY 2025 Results

Cricut (CRCT) just wrapped up FY 2025 with fourth quarter revenue of US$203.6 million and basic EPS of US$0.04, alongside net income of US$7.8 million, setting the tone for how the full year is being read by the market. The company has seen quarterly revenue shift from US$209.3 million with EPS of US$0.06 in Q4 2024 to US$203.6 million with EPS of US$0.04 in Q4 2025. Trailing twelve month EPS sits at US$0.36 on revenue of US$708.8 million, and that mix of steady top line and improving...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Mixed Recent Returns And A 5.7% Undervaluation Estimate

Recent performance snapshot for Jazz Pharmaceuticals (JAZZ) Jazz Pharmaceuticals (JAZZ) has attracted attention after a period of mixed short term moves and stronger longer term returns, with the stock closing at $188.69 and showing positive figures across several multi year horizons. See our latest analysis for Jazz Pharmaceuticals. Recent moves have been choppy, with a 1 day share price return of 1.08% and a 7 day share price return showing a 4.14% decline. However, the 30 day share price...
NasdaqCM:SRTA
NasdaqCM:SRTAHealthcare

Strata Critical Medical Q4 Loss Underscores Ongoing Profitability Gap Versus Bullish Narratives

Strata Critical Medical (SRTA) has reported its FY 2025 numbers, with Q4 revenue at US$66.8 million and a basic EPS loss of US$0.06. Trailing twelve month revenue came in at US$197.1 million with a full year basic EPS loss of US$0.24. Over recent quarters, the company has reported revenue in a range from US$36.1 million to US$66.8 million, while quarterly basic EPS losses have moved between US$0.04 and US$0.12. This keeps the focus on how efficiently it is converting sales into earnings. With...
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Bank of America’s Robotaxi Focus Could Be A Game Changer For Tesla’s (TSLA) Investment Narrative

In recent days, Bank of America reinstated coverage of Tesla, highlighting its leadership in consumer-focused autonomy, robotaxis operating in cities like Austin and San Francisco, and longer-term opportunities in Optimus humanoid robots and energy storage. This renewed analyst focus underscores how Tesla’s push to become a “physical AI” and software-led mobility platform is increasingly central to how investors view the business, beyond its core electric vehicle sales. We’ll now examine...
NYSE:CTRE
NYSE:CTREHealth Care REITs

Assessing CareTrust REIT’s (CTRE) Valuation After Earnings Beat And Expansion Into UK Care Properties

CareTrust REIT (CTRE) is back in focus after reporting earnings and revenue that exceeded analyst estimates, while also expanding its healthcare property footprint through acquisitions in the United States and the United Kingdom. See our latest analysis for CareTrust REIT. At a recent share price of US$39.29, CareTrust REIT has seen a 7.9% 1 month share price return and an 8.2% year to date share price return. Its 1 year total shareholder return of 54.3% and 3 year total shareholder return...
NYSE:TPL
NYSE:TPLOil and Gas

Texas Pacific Land (TPL) Valuation After Record Results And New Power And Data Center Prospects

Texas Pacific Land (TPL) is back in focus after record Q4 and full year results, with rising oil and gas royalty volumes, strong water sales, insider buying, and fresh interest around power and data center projects. See our latest analysis for Texas Pacific Land. That backdrop of record results, data center and power opportunities, and steady insider buying has coincided with sharp momentum, with a 59.23% 1 month share price return and a 277.03% 5 year total shareholder return suggesting...